Bruce R. Yacyshyn, M.D., FRCPC, FACG, AGAF

Bruce R. Yacyshyn, M.D., FRCPC, FACG, AGAF

Bruce R. Yacyshyn, M.D., FRCPC, FACG, AGAF

  • Professor of Medicine
UofL Physicians Outpatient Center
401 East Chestnut Street, Ste. 310
Louisville, KY 40202

502-852-6991 - Academic Office
502-588-4600 - Patient Appointments

Clinical Expertise

Board Certifications

  • American Board of Internal Medicine -
    Internal Medicine

Education and Training

  • Medical School: University of Alberta
  • Residency: University of Toronto General Hospital
  • Fellowship: Washington University in St. Louis

Featured Publications

  • Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 Feb;158(3):550-561. doi: 10.1053/j.gastro.2019.10.035. Epub 2019 Nov 9. PubMed PMID: 31711921.
  • Shah ED, Beaulieu DB, Yacyshyn B; ACG FDA Related Matters Committee. Accessing Food and Drug Administration Resources in Clinical Practice: A Primer for the Practicing Gastroenterologist. Am J Gastroenterol. 2019 Oct;114(10):1688-1690. doi: 10.14309/ajg.0000000000000392. PubMed PMID: 31464738.
  • Lee P, Yacyshyn BR, Yacyshyn MB. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT). Diabetes Obes Metab. 2019 Mar;21(3):479-490. doi: 10.1111/dom.13561. Epub 2018 Nov 20. Review. PubMed PMID: 30328245.
  • Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for recurrence. Clin Infect Dis. 2018 Aug 16;67(5):649-656. doi: 10.1093/cid/ciy171. PubMed PMID: 29538686; PubMed Central PMCID: PMC6093994.
  • Coffing H, Priyamvada S, Anbazhagan AN, Salibay C, Engevik M, Versalovic J, Yacyshyn MB, Yacyshyn B, Tyagi S, Saksena S, Gill RK, Alrefai WA, Dudeja PK. Clostridium difficile toxins A and B decrease intestinal SLC26A3 protein expression. Am J Physiol Gastrointest Liver Physiol. 2018 Jul 1;315(1):G43-G52. doi: 10.1152/ajpgi.00307.2017. Epub 2018 Mar 29. PubMed PMID: 29597352; PubMed Central PMCID: PMC6109705.
  • Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017 Jul;17(7):735-744. doi: 10.1016/S1473-3099(17)30235-9. Epub 2017 Apr 28. PubMed PMID: 28461207; PubMed Central PMCID: PMC5483507.
  • Nalapareddy K, Nattamai KJ, Kumar RS, Karns R, Wikenheiser-Brokamp KA, Sampson LL, Mahe MM, Sundaram N, Yacyshyn MB, Yacyshyn B, Helmrath MA, Zheng Y, Geiger H. Canonical Wnt Signaling Ameliorates Aging of Intestinal Stem Cells. Cell Rep. 2017 Mar 14;18(11):2608-2621. doi: 10.1016/j.celrep.2017.02.056. PubMed PMID: 28297666; PubMed Central PMCID: PMC5987258.
  • Yacyshyn B. Pathophysiology of Clostridium difficile-Associated Diarrhea. Gastroenterol Hepatol (N Y). 2016 Sep;12(9):558-560. PubMed PMID: 27917094; PubMed Central PMCID: PMC5114514.
  • Matthis AL, Zhang B, Denson LA, Yacyshyn BR, Aihara E, Montrose MH. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802. doi: 10.1097/MIB.0000000000000823. PubMed PMID: 27416043; PubMed Central PMCID: PMC4956520.
  • Aihara E, Matthis AL, Karns RA, Engevik KA, Jiang P, Wang J, Yacyshyn BR, Montrose MH. Epithelial Regeneration After Gastric Ulceration Causes Prolonged Cell-Type Alterations. Cell Mol Gastroenterol Hepatol. 2016 May 17;2(5):625-647. eCollection 2016 Sep. PubMed PMID: 27766298; PubMed Central PMCID: PMC5042868.